Search for: "BOEHRINGER INGELHEIM PHARMA GMBH "
Results 1 - 20
of 33
Sort by Relevance
|
Sort by Date
26 Oct 2021, 12:41 am
On 8 October 2021, His Honour Judge Hacon (sitting as a Judge of the High Court) handed down his decision in an action brought by Royalty Pharma Collection Trust (“Royalty Pharma”) for approximately €23 million in royalty payments from Boehringer Ingelheim GmbH (“Boehringer”) (Royalty Pharma Collection Trust v Boehringer Ingelheim GmbH [2021] EWHC 2692 (Pat)). [read post]
26 Oct 2021, 12:41 am
On 8 October 2021, His Honour Judge Hacon (sitting as a Judge of the High Court) handed down his decision in an action brought by Royalty Pharma Collection Trust (“Royalty Pharma”) for approximately €23 million in royalty payments from Boehringer Ingelheim GmbH (“Boehringer”) (Royalty Pharma Collection Trust v Boehringer Ingelheim GmbH [2021] EWHC 2692 (Pat)). [read post]
9 Jul 2018, 10:00 pm
More from our authors: Mediation: Creating Value in International Intellectual Property Disputes by Théophile Margellos, Sophia Bonne, Gordon Humphreys, Sven Stürmann € The post Ireland: Re Boehringer Ingelheim Pharma GmbH & Co. [read post]
2 Jun 2018, 5:55 am
A full summary of this case has been published on Kluwer IP Law More from our authors: Mediation: Creating Value in International Intellectual Property Disputes by Théophile Margellos, Sophia Bonne, Gordon Humphreys, Sven Stürmann € The post United Kingdom: Teva UK Ltd v Boehringer Ingelheim Pharma GmbH & Co KG, Court of Appeal of England and Wales, Civil Division,… [read post]
4 May 2017, 1:00 am
Relevant Judicial Practice Boehringer Ingelheim Pharma GmbH & Co KG v. [read post]
24 Feb 2017, 1:31 am
€ 160 The post United Kingdom: Teva UK Ltd v Boehringer Ingelheim Pharma GmbH & Co KG, Court of Appeal of England and Wales, Civil Division, A3 2016 0271, 16 December 2016 appeared first on Kluwer Patent Blog. [read post]
30 Dec 2016, 2:58 pm
Permission to appeal in patent cases - farewell to the Pozzoli approachGuest Kat Eibhlin Vardy recaps the case Teva UK Ltd v Boehringer Ingelheim Pharma GmbH & Co KG, [2016] EWCA Civ 1296. [read post]
21 Dec 2016, 12:48 am
These are the issues considered by the Court of Appeal in last week's decision concerning an application for permission to appeal in Teva UK Ltd v Boehringer Ingelheim Pharma GmbH & Co KG [2016] EWCA Civ 1296. [read post]
15 Nov 2016, 2:00 pm
Boehringer Ingelheim GMBH, 237F.3d 1359, 1365 (Fed. [read post]
8 May 2016, 9:59 pm
Boehringer Ingelheim Pharma GmbH & Co. [read post]
16 Mar 2015, 3:10 am
CJEU rules in telmisartan SPC disputeAfter his own earlier post on the CJEU’s decision in Case C‑577/13, Actavis Group PTC EHF, Actavis UK Ltd v Boehringer Ingelheim Pharma GmbH & Co. [read post]
12 Mar 2015, 11:09 am
Today's the day that many pharmaceutical patent term extension-watchers have been waiting for with feelings of optimism or anxiety: the day on which the Court of Justice of the European Union (CJEU) delivered its ruling in Case C‑577/13, Actavis Group PTC EHF, Actavis UK Ltd v Boehringer Ingelheim Pharma GmbH & Co. [read post]
13 Feb 2014, 6:00 am
District Court Judge David Herndon from the Southern District of Illinois imposed close to $1 million in punitive damages on defendants Boehringer Ingelheim International GMBH (“BII”) and Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
2 Nov 2010, 1:40 am
AstraZeneca sought and got a preliminary injunction against Apotex, which was hankering to launch a generic version of the asthma drug Pulmicort. [read post]
27 May 2010, 3:20 am
Boehringer Ingelheim International GMBH et al. [read post]
13 May 2010, 4:58 pm
(FDA Law Blog) US: Divisional of a divisional: Avoid terminal disclaimers: CAFC denies en banc rehearing in Boehringer Ingelheim International GMBH v. [read post]
5 May 2010, 4:46 am
Aurobindo Pharma Ltd. et al. [read post]
1 May 2010, 11:00 am
The present decision deals with the refusal of an application on the ground of unallowable double patenting. [read post]
10 Mar 2010, 5:22 am
(FDA Law Blog) US: Review and correction of patent term adjustment calculation made by the USPTO: Boehringer Ingelheim Pharma GmbH & Co. [read post]
10 Mar 2010, 5:22 am
(FDA Law Blog) US: Review and correction of patent term adjustment calculation made by the USPTO: Boehringer Ingelheim Pharma GmbH & Co. [read post]
